Phaseline

Targets › DNAG

DNAG: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Immunology, Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on DNAG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nishtar Medical Universitynadifloxacin
Fluoroquinolone antibiotic with broad-spectrum activity against acne-causing bacteria
DNAG, DNABPhase 4Acne VulgarisMar 2027
Tanta UniversityGemifloxacin
Fluoroquinolone; topoisomerase II (DNA gyrase) and topoisomerase IV inhibitor
DNAG, DNABPhase 3Spontaneous Bacterial PeritonitisDec 2028

Conditions

Acne Vulgaris (1) Spontaneous Bacterial Peritonitis (1)

Modalities

small molecule (2)

Companies

Nishtar Medical University (1) Tanta University (1)

Related targets

DNAB (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.